Edition:
United States

Oncopeptides AB (ONCO.ST)

ONCO.ST on Stockholm Stock Exchange

78.70SEK
22 Feb 2018
Change (% chg)

-1.30kr (-1.62%)
Prev Close
80.00kr
Open
79.60kr
Day's High
80.00kr
Day's Low
77.20kr
Volume
19,821
Avg. Vol
44,843
52-wk High
96.00kr
52-wk Low
41.10kr

Latest Key Developments (Source: Significant Developments)

Oncopeptides Q4 Net Loss Up At Sek ‍66.7​ Million
2:00am EST 

Feb 22 (Reuters) - Oncopeptides Ab ::Q4 NET LOSS SEK ‍66.7​ MILLION VERSUS LOSS SEK 51.1 MILLION YEAR AGO.  Full Article

Oncopeptides Q3 operating ‍loss widens to SEK 51.6 million
Wednesday, 15 Nov 2017 02:04am EST 

Nov 15 (Reuters) - ONCOPEPTIDES AB :Q3 OPERATING ‍LOSS SEK 51.6 MILLION VERSUS LOSS SEK 24.7 MILLION YEAR AGO​.  Full Article

Oncopeptides Q2 loss for period widens to SEK 67.3 mln​
Friday, 25 Aug 2017 02:00am EDT 

Aug 25 (Reuters) - ONCOPEPTIDES AB :‍Q2 LOSS FOR PERIOD WAS 67.3 (LOSS: 23.5) MSEK​.  Full Article

Oncopeptides Q1 net loss SEK 62.1 million
Thursday, 18 May 2017 02:00am EDT 

May 18 (Reuters) - ONCOPEPTIDES AB :Q1 NET SALES AMOUNTED TO 0.0 (0.0) MSEK.Q1 LOSS FOR PERIOD WAS 62.1 (LOSS: 15.2) MSEK.  Full Article

Oncopeptides receives additional patent protection for Ygalo in Europe
Tuesday, 21 Mar 2017 03:45am EDT 

Oncopeptides AB : European patent office recently issued a notice that they intend to grant an additional European patent to Oncoeptides . Additional patent protection for Ygalo is valid April 2032 .Patent (EP2701720) covers inter alia lyophilized formulation of Ygalo that is intended to be launched.  Full Article

BRIEF-Oncopeptides Q4 Net Loss Up At Sek ‍66.7​ Million

* Q4 NET LOSS SEK ‍66.7​ MILLION VERSUS LOSS SEK 51.1 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)